期刊文献+

内皮型一氧化氮合酶腺病毒表达载体的构建与鉴定 被引量:1

Construction and identification of adenovirus expression vector for endothelial nitric oxide synthase
下载PDF
导出
摘要 目的 构建重组内皮型一氧化氮合酶(eNOS)腺病毒表达系统载体。方法 eNOS的cDNA插入pcDNA3.1(-)中,进行DNA测序、酶切鉴定;插入片段用Xbal和AflⅡ双酶切后连接到pshuttle中,并予酶切鉴定;用P1-sce Ⅰ和Ⅰ-ceu Ⅰ双酶切下pshuttle中eNOS的cDNA插入腺病毒载体,通过PCR鉴定。结果 正确构建重组eNOS腺病毒表达系统,并被目的基因的PCR鉴定证实。结论 重组腺病毒表达载体构建正确,为其在预防经皮腔内动脉成形术术后再狭窄基因转染奠定基础。 Objective To construct recombinant endothelial nitric oxide synthase ( eNOS) adenovirus for evaluating the possibility of gene therapy in restenosis. Methods eNOS cDNA was inserted to pcDNA3. 1( - ) vector, identified by DNA analysis and restriction endonuclease analysis . The inserted cDNA was excised with Xba Ⅰ and Afl Ⅱ , cloned to pshuttle vector. Pshuttle-eNOS was identified by restriction endonuclease analysis, excised with Pl-sce Ⅰ and Ⅰ-ceu Ⅰ , then cloned into adenoviral DNA. An adenovirus expression vector for endothelial NO synthase (AdCMV-eNOS) was identified by PCR. Results The recombinant adenoviral vector for endothelial nitric oxide synthase was correctly constructed and confirmed by PCR method. Conclusion The recombinant vector can be constructed correctly, which establishes the base for eNOS transfection in the prevention of postangioplasty restenosis.
出处 《上海第二医科大学学报》 CSCD 2004年第9期717-719,共3页 Acta Universitatis Medicinalis Secondae Shanghai
基金 上海市教委基金(01B02)资助项目.
关键词 腺病毒 NOS 内皮型一氧化氮合酶 鉴定 动脉成形术 腔内 PCR 表达系统 酶切 表达载体 percutaneous transluminal coronary angioplasty endothelial nitric oxide synthase adenovirus
  • 相关文献

参考文献9

  • 1Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease[ J]. N Engl J Med, 1994, 331(8): 489 -495.
  • 2Hecker M, Cattaruzza M, Wagner AH. Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells[J]. GenPharmacol, 1999, 32(1): 9-16.
  • 3Janero DR, Ewing JF. Nitric oxide and postangioplasty restenosis:pathological correlates and therapeutic potential [ J ]. Free Radic Biol Med, 2000, 29(12): 1 199 -1 221.
  • 4Jeremy JY, Rowe D, Emsley AM, et al. Nitric oxide and the proliferation of vascular smooth muscle cells[ J]. Cardiovasc Res, 1999,43: 580 - 594.
  • 5Chen AF, Ren J, Miao CY. Nitric oxide synthase gene therapy for cardiovascular disease[ J]. Jpn J Pharmacol, 2002, 89(4): 327 -336.
  • 6Zhang WW. Development and application of adenoviral vector gene therapy of cancer[J]. Cancer Gene Ther, 1999, 6(2): 113 -389.
  • 7Deng W, Bivalacqua TJ, Chattergoon NN, et al. Adenoviral gene transfer of eNOS: high-level expression in exvivo expanded marrow stromal cells[ J]. Am J Physiol Cell Physiol, 2003,285 (5): 1 322- 1 329.
  • 8Janssens S, Flaherty D, Nong Z, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats[ J].Circulation, 1998, 97:1 274-1 281.
  • 9Varenne O, Pislaru S, Gillijns H, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pig[ J]. Circulation, 1998,98:919-926.

同被引文献12

  • 1蔡文玮,陆平,盛净.eNOS基因体外转染对大鼠颈总动脉球囊损伤后血管平滑肌细胞增殖规律的影响[J].中国微循环,2005,9(4):251-254. 被引量:3
  • 2KOPP C W, de MARTIN R. Gene therapy approaches for the prevention of restenosis [ J ]. Curr Vasc Pharmacol, 2004,2 (2) :183-189.
  • 3KIM S E, PARK J H, CHO Y W, et al. Porous chitosan scaffold containing microspheres loaded with transforming growth factor beta 1 : implications for cartilage tissue engineering[J]. J Control Release,2003,91 (3) :365-374.
  • 4TAKAKURA Y, NISHIKAWA M, YAMASHITA F. Influence of physicochemical properties on pharmaeokinetics of non-viral vectors for gene delivery [ J ] J Drug Target, 2002, 10 ( 2 ) : 99-104.
  • 5KUZNETSOV A A, FILIPPOV V L, KUZNETSOV O L, et al. New ferro-carbor absorbents for magnetically guided transport of anticancer drugs [ J ]. J Magu Magu Mater, 1999,194:22-30.
  • 6KIMA E H, AHNB Y, LEE H S. Biomedical applications of superparamagnetic iron oxide nanoparticles encapsulated within chitosan[ J]. J Alloys Compd,2007,434/435:633-636.
  • 7HORLITZ M, SIGWART U, NIEBAUER J. Fighting restenosis after coronary angioplasty: contemporary and future treatment options [ J ]. Int J Cardiol, 2002,83 ( 3 ) : 199-205.
  • 8JANSSENS S, FLAHERTY D, NONG Z, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats [ J ]. Circulation, 1998,97 (13) : 1274-1281.
  • 9CHEN A F, REN J, MIAO C Y. Nitric oxide synthase gene therapy for cardiovascular disease [ J ]. Jpn J Pharmacol, 2002,89 (4) :327-336.
  • 10ZHANG W W. Development and application of adenoviral vector gene therapy of cancer[ J]. Cancer Gene Ther, 1999, 6(2) :113-389.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部